OBJECTIVE: Electroconvulsive therapy (ECT) is a widely used and effective treatment for mood disorders and appears to have positive effects on the motor symptoms of Parkinson's disease (PD), improving motor function for several weeks. Because repeated electroconvulsive shock (ECS) in normal animals enhances striatal dopamine (DA) D(1) and D(3) receptor binding, we hypothesized that upregulation of D(1) and D(3) receptors may also be occurring in the parkinsonian brain after repeated ECS treatment. METHODS: Rats were rendered hemi-parkinsonian through unilateral infusion of the DA-specific neurotoxin 6-hydroxydopamine into the medial forebrain bundle and substantia nigra. The animals were tested for hindlimb and forelimb function before and 48 hours after the last of 10 daily treatments with ECS or sham. After sacrifice, DA receptor binding was determined autoradiographically. RESULTS: While there was no increase in forelimb use in the cylinder test, ECS treatment significantly improved hindlimb motor performance on a tapered beam-walking test and enhanced striatal D(1) and D(3) receptor binding, without affecting D(2) receptor binding. CONCLUSION: This study suggests that at least part of the mechanism of action of ECT in PD may be enhanced DA function within the direct pathway of the basal ganglia and may support the further study and use of ECT as a potential adjunct treatment for PD.
OBJECTIVE: Electroconvulsive therapy (ECT) is a widely used and effective treatment for mood disorders and appears to have positive effects on the motor symptoms of Parkinson's disease (PD), improving motor function for several weeks. Because repeated electroconvulsive shock (ECS) in normal animals enhances striatal dopamine (DA) D(1) and D(3) receptor binding, we hypothesized that upregulation of D(1) and D(3) receptors may also be occurring in the parkinsonian brain after repeated ECS treatment. METHODS:Rats were rendered hemi-parkinsonian through unilateral infusion of the DA-specific neurotoxin 6-hydroxydopamine into the medial forebrain bundle and substantia nigra. The animals were tested for hindlimb and forelimb function before and 48 hours after the last of 10 daily treatments with ECS or sham. After sacrifice, DA receptor binding was determined autoradiographically. RESULTS: While there was no increase in forelimb use in the cylinder test, ECS treatment significantly improved hindlimb motor performance on a tapered beam-walking test and enhanced striatal D(1) and D(3) receptor binding, without affecting D(2) receptor binding. CONCLUSION: This study suggests that at least part of the mechanism of action of ECT in PD may be enhanced DA function within the direct pathway of the basal ganglia and may support the further study and use of ECT as a potential adjunct treatment for PD.
Authors: Ann D Cohen; Jennifer L Tillerson; Amanda D Smith; Timothy Schallert; Michael J Zigmond Journal: J Neurochem Date: 2003-04 Impact factor: 5.372
Authors: K Yoshida; H Higuchi; M Kamata; M Yoshimoto; T Shimizu; Y Hishikawa Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 1998-02 Impact factor: 5.067
Authors: N R Williams; B S Bentzley; G L Sahlem; J Pannu; J E Korte; G Revuelta; E B Short; M S George Journal: Acta Neurol Scand Date: 2016-05-31 Impact factor: 3.209
Authors: Anne M Landau; M Mallar Chakravarty; Campbell M Clark; Athanasios P Zis; Doris J Doudet Journal: Neuropsychopharmacology Date: 2010-10-13 Impact factor: 7.853
Authors: Juuso V Leikas; Samuel Kohtala; Wiebke Theilmann; Aaro J Jalkanen; Markus M Forsberg; Tomi Rantamäki Journal: J Neurochem Date: 2017-06-14 Impact factor: 5.372
Authors: M G A Van Cauwenberge; F Bouckaert; K Vansteelandt; C Adamson; F L De Winter; P Sienaert; J Van den Stock; A Dols; D Rhebergen; M L Stek; L Emsell; M Vandenbulcke Journal: Transl Psychiatry Date: 2021-04-01 Impact factor: 6.222